A5084398427- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Testicular diseases and treatments
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Radiomics and Machine Learning in Medical Imaging
- Infectious Disease Case Reports and Treatments
- Genital Health and Disease
- Adrenal and Paraganglionic Tumors
- Surgical Simulation and Training
- Sarcoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Hormonal Regulation and Hypertension
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Screening and Detection
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Soft tissue tumor case studies
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Surgical Treatments
- Tissue Engineering and Regenerative Medicine
Université de Montréal
2022-2025
European Institute of Oncology
2020-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2024
Ripamonti
2020-2024
University of Milan
1968-2024
Cytodiagnostics (Canada)
2024
Centre Hospitalier de l’Université de Montréal
2023
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2019-2020
Nanjing Medical University
2019
Ospedale Maggiore
2019
Abstract To test for rates of inpatient palliative care (IPC) in metastatic testicular cancer patients receiving critical therapy (CCT). Within the Nationwide Inpatient Sample (NIS) database (2008–2019), we tabulated IPC CCT, namely invasive mechanical ventilation (IMV), percutaneous endoscopic gastrostomy tube (PEG), dialysis acute kidney failure (AKF), total parenteral nutrition (TPN) or tracheostomy. Univariable and multivariable logistic regression models addressing were fitted. Of 420...
We designed a phase 3, prospective, randomized trial to evaluate the impact of augmented reality and frozen section analysis in reducing rates positive surgical margins after robot-assisted radical prostatectomy.
This study aimed to test for temporal trends of in-hospital venous thromboembolism (VTE) and pulmonary embolism (PE) after major urologic cancer surgery (MUCS).In the Nationwide Inpatient Sample (NIS) database (2010-2019), this identified non-metastatic radical cystectomy (RC), prostatectomy (RP), nephrectomy (RN), partial (PN) patients. Temporal VTE PE multivariable logistic regression analyses (MLR) addressing or PE, mortality with were performed.Of 196,915 patients, 1180 (1.0%) exhibited...
Background Current predictive tools to estimate the risk of biochemical recurrence (BCR) after treatment prostate cancer do not consider multiparametric MRI (mpMRI) information. Purpose To develop a prediction tool that considers mpMRI findings assess 5-year BCR radical prostatectomy. Materials and Methods In this retrospective single-center analysis in 1459 patients with who underwent before prostatectomy (in 2012-2015), outcome interest was (two consecutive prostate-specific antigen [PSA]...
To test the performance of ex vivo fluorescence confocal microscopy (FCM; Vivascope 2500M-G4), as compared to intra-operative frozen section (IFS) analysis, evaluate surgical margins during robot-assisted radical prostatectomy (RARP), with final pathology reference standard.
Background It is unknown whether 5‐year overall survival (OS) differs and to what extent between the American Joint Committee on Cancer stage III non‐seminoma testicular germ cell tumor (NS‐TGCT) patients simulated age‐matched male population‐based controls, according race/ethnicity groups. Methods We identified newly diagnosed (2004–2014) NS‐TGCT within Surveillance Epidemiology End Results database 2004–2019. For each case, we an control (Monte Carlo simulation), relying Social Security...
We aimed at assessing the impact of non-urothelial variant histology (VH), relative to urothelial carcinoma urinary bladder (UCUB), on cancer-specific mortality (CSM) in T2N0M0 cancer patients treated with trimodal therapy (TMT). TMT for were identified within Surveillance, Epidemiology, and End Results database (2000−2018). Patients who underwent received trans-urethral resection tumor, chemotherapy, radiotherapy. CSM-FS rates tested using Kaplan–Meier plots multivariable Cox-regression...
Within the Surveillance, Epidemiology, and End Results database (2000–2019), we identified 5522 unilateral surgically treated non-metastatic chromophobe kidney cancer (chRCC) patients. This population was randomly divided into development vs. external validation cohorts. In cohort, original Leibovich 2018 GRANT categories were applied to predict 5- 10-year cancer-specific survival (CSS). Subsequently, a novel multivariable nomogram developed. Accuracy, calibration decision curve analyses...
Guidelines recommend VENUSS and GRANT models for the prediction of cancer control outcomes after nephrectomy nonmetastatic papillary renal cell carcinoma (pRCC).To test ability to predict 5-yr cancer-specific survival in a North American population.For this retrospective study, we identified 4184 patients with unilateral surgically treated pRCC Surveillance, Epidemiology, End Results database (2004-2019).The original risk categories were applied survival. A cross-validation method was used...
Purpose To assess whether 5‐year overall survival (OS) of squamous cell carcinoma the penis (SCCP) patients differs from age‐matched male population‐based controls. Methods We relied on Surveillance Epidemiology and End Results database (2004–2018) to identify newly diagnosed (2004–2013) SCCP patients. For each case, we simulated an control (Monte Carlo simulation), relying Social Security Administration (SSA) Life Tables with 5 years follow‐up. compared OS between controls in a...